Does BBIO pay a dividend and is it safe?

BridgeBio Pharma Inc. (BBIO) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / BBIO / dividends

JAZZ (49) ASND (69) SMMT (40) RDY (64) ⌘ Pro Terminal →

BridgeBio Pharma Inc. (BBIO) Dividend Safety Gauge & 10-Year DRIP Compounder

$75.00 +0.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $74.87

BridgeBio Pharma Inc. (BBIO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $14.60B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BridgeBio Pharma Inc. (NASDAQ: BBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $75.00 (+0.06% 1D, market cap $14.60B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BBIO ranks #619 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBIO compare to JAZZ and ASND in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBIO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 95.8%, and ROIC of -35.0%. By comparison, JAZZ (Jazz Pharmaceuticals plc (Ireland)) holds a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B) and ASND (Ascendis Pharma A/S Ordinary Share) posts a C+ grade (69/100 RQD, P/E 32.8x, ROIC 9.9%, cap $16.55B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBIO?

▼

Per BBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001743881), BridgeBio Pharma Inc. generated $502.1M in revenue (+126.3% YoY), $0 in net income, and -$447.0M in free cash flow against $936.0M in total assets and $1.36B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $74.86 (-0.18%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBIO)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY BBIO SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (41% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (21% of score)

FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 63.9 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$64.94+4.3% Next Q

Q2 (-2Q)

Grade E$67.74+4.5% Next Q

Q3 (-1Q)

Grade E$70.82+5.9% Next Q

Current

Grade E$75.00-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBIO currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($69.74) and Max Pain ($78.75) forces dealer call-delta covering toward $98.09.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBIO)

✓Walkthrough of BBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.71%⚡ TESTING RESISTANCE

2026-11-03O $70.73H $75.00L $70.73C $75.00VOL 5.77M

RES: $75.13SUP: $62.35SMA50: $69.74SMA200: $72.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBIO Butterfly Map → + Track BBIO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.5%/yr Implied 5Y Growth

vs. +126.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBIO)

Health Care Rank #619 of 1016 ⚔️ JAZZ vs BBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBIO vs. JAZZ, ASND, SMMT, RDY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BridgeBio Pharma Inc. (BBIO) ranks #619 by composite RQD confidence (34/100, grade E) and #82 by equity capitalization ($14.60B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with BBIO at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BBIO ACTIVE BridgeBio Pharma Inc.	E	34/100	—	95.8%	-35.0%	+0.06%	$14.60B	Benchmark Subject
JAZZ Jazz Pharmaceuticals plc (Ireland)	D	49/100	—	—	-4.7%	-0.71%	$14.02B	/jazz-vs-bbio →
ASND Ascendis Pharma A/S Ordinary Share	C+	69/100	32.8x	—	9.9%	-0.91%	$16.55B	/asnd-vs-bbio →
SMMT Summit Therapeutics Inc.	D-	40/100	—	—	-35.0%	-7.67%	$12.82B	/smmt-vs-bbio →
RDY Dr. Reddy's Laboratories Ltd	C	64/100	32.8x	—	9.9%	-0.28%	$11.83B	/rdy-vs-bbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001743881

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BridgeBio Pharma Inc. (BBIO) reported GAAP revenue of $502.1M (+126.3% vs. FY2024 revenue of $221.9M , and +5296.9% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$445.9M, and free cash flow of -$447.0M (+14.3% YoY). On the balance sheet, BBIO closed FY2025 with $936.0M in total assets against $1.36B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$502.1M	$0	-$445.9M	-$447.0M	$936.0M	$1.36B
FY2024 (FY)	2024-12-31	$221.9M	$0	-$520.7M	-$521.7M	$919.3M	$437.3M
FY2023 (FY)	2023-12-31	$9.3M	$0	-$527.7M	-$528.1M	$7.60B	$1.78B

3. BBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BBIO compare to JAZZ and ASND in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BBIO?

Where is BBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

BBIO last traded at $75.00 (+0.06% on volume of 3,097,274 shares), positioning the stock +7.54% above its 50-day simple moving average ($69.74) and +3.19% above its 200-day simple moving average ($72.68). Across its 52-week range of $60.22 to $93.42, BBIO sits at the 44.5% percentile with a 14-day RSI of 63.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.5% ($70.12 to $79.88).

Direct Sub-Reports: BBIO RQD Cockpit BBIO 12M Forecast BBIO Earnings & Move BBIO Dividends & DRIP BBIO Insiders & 13F BBIO Whale Options BBIO Profit Sankey BBIO News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

BBIO — BridgeBio Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BridgeBio Pharma Inc. (BBIO) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $75.00 (+0.06% 1D, market capitalization $14.60B).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 95.8%, operating margin of -60.0%, and free cash flow yield of -3.23%.
Whale 13F & Options Flow (14/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 4/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

BridgeBio Pharma Inc. Is a NASDAQ-listed company classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $502.1M in FY 2025, up from $221.9M in FY 2024 and $9.3M in FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BridgeBio Pharma Inc. (BBIO) reported $502.1M in annual revenue (up from $221.9M in FY2024, +126.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.3M revenue, $0 net income) through FY2025, BBIO scaled operating cash flow to -$445.9M and free cash flow to -$447.0M, backed by $936.0M in total assets against $1.36B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.23% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $60.22 – $93.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BBIO carries a macro regime beta of 1.00 and gross margin of 95.8%.

Key Question #1: Can BBIO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $502.1M and free cash flow of -$447.0M, how will capital allocation balance growth reinvestment against $1.36B in total debt?
Key Question #3: How sensitive is BBIO's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BridgeBio Pharma Inc. (BBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBIO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Where Does BridgeBio Pharma (BBIO) Value Sit After Trial Wins?

Yahoo Finance report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

Seeking Alpha report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Should You Invest $1,000 in BridgeBio Pharma Right Now?

The Motley Fool report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

What BridgeBio Pharma Doubters Missed

Yahoo Finance report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results f

GuruFocus report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocks Down Under • 1d ago

BridgeBio Pharma (NDQ:BBIO): 5 Years From A Near-Death Experience, Its Has A Cumulative Opportunity Of ~$30bn At Its Fingertips!

Stocks Down Under report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

32 new hires get awards tied to 57,853 shares, but vesting depends on continued employment.

Stock Titan report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

BridgeBio Pharma (BBIO) Stock Jumps As Q3 Results Fuel Revenue Optimism

Simply Wall St report covering BridgeBio Pharma Inc. (BBIO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBIO Bull vs. Bear Conversation Board — What's Your Call at $75.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBIO 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $95.19 (+27.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 12/20, the strongest pillar, alongside reported positive Phase 3 trial results

Institutional accumulation and options positioning score 12/20, the strongest pillar, alongside reported positive Phase 3 trial results in the news feed.. When you look under the hood at BBIO, Fundamental Cash Engine is 3/20 with 95.8% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (14/20) has been quietly accumulating below $93.42. My 12M target is $95.19.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 14/20 institutional whale-flow stock at $74.95 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $62.21 (-17.0%)

Spot @ $74.95

Negative ROIC of -35%, FCF of -$447.0M, Altman Z of 0.45, and debt rising to $1.36B against falling cash signal substantial forensic

Negative ROIC of -35%, FCF of -$447.0M, Altman Z of 0.45, and debt rising to $1.36B against falling cash signal substantial forensic and cash-generation risk.. Look at the math on BBIO: paying 33.0x forward P/E for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $65.96 before getting long.